Fintel reports that on January 16, 2025, Cantor Fitzgerald initiated coverage of NICE - Depositary Receipt () (NasdaqGS:NICE) ...

Fintel reports that on January 17, 2025, Cantor Fitzgerald downgraded their outlook for Polestar Automotive Holding UK PLC - ...

Analysts at Cantor Fitzgerald upped their FY2024 earnings per share (EPS) estimates for shares of Rigel Pharmaceuticals in a ...

There is no Morningstar’s Analysis data available. We sell different types of products and services to both investment professionals and individual investors. These products and services are ...

Cantor Fitzgerald analyst Jonathan Ruykhaver raised the firm’s price target on CrowdStrike (CRWD) to $410 from $370 and keeps an Overweight ...

Cantor Fitzgerald is charged with violating antifraud and proxy provisions. Former Comtech CEO is charged with insider trading ahead of negative earnings. The Securities and Exchange Commission on ...

Cantor Fitzgerald initiated coverage of Nice (NICE) with a Neutral rating and $176 price target Stay Ahead of the Market:Discover outperforming ...

Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) was upgraded by equities research analysts at Cantor Fitzgerald from ...

Cantor Fitzgerald reiterates an Overweight rating on Avita Medical (RCEL) following the company receiving FDA premarket approval for RECELL GO Mini, its miniaturized device designed to treat ...

Cantor Fitzgerald assumed coverage of Zevra Therapeutics (ZVRA) with an Overweight rating and $25 price target Zevra is a rare disease, commercial-stage biotechnology company with two approved ...

Cantor Fitzgerald Large Cap Focused Fund earns an Above Average Process Pillar rating. The most substantial contributor to the rating is the parent firm's five-year risk-adjusted success ratio of 90%.